Eyetech Vision Day to Preview Future of Macugen Franchise Top Eyetech Executives and Ophthalmology Researchers to Present at Event This Wednesday, June 22, at 11:45 A.M. NEW YORK, June 21 /PRNewswire-FirstCall/ -- WHEN: Wednesday, June 22 NEW time: 11:45 a.m. to 2:30 p.m. Eastern time* *Please join us for lunch at 11:45 a.m. Presentations will begin promptly at 12:15 p.m. WHERE: The Westin New York Hotel at Times Square 270 West 43rd Street (at 8th Avenue), New York City Broadway Ballroom (third floor) WHAT: Eyetech Pharmaceuticals, makers of Macugen(R) (pegaptanib sodium injection) -- the first anti-VEGF therapy indicated for the treatment of all subtypes of neovascular AMD -- will present details about the Macugen franchise and novel therapies in the pipeline. WHO: Information will be presented by top scientific researchers and senior corporate executives, including: * Anthony P. Adamis, M.D., Executive Vice President of Research and Development and Chief Scientific Officer of Eyetech * Donald D'Amico, M.D., Professor of Ophthalmology at the Massachusetts Eye and Ear Infirmary at Harvard Medical School, and a member of the Eyetech Scientific Advisory Board * Errol De Souza, Ph.D., President and Chief Executive Officer of Archemix Corp. * David R. Guyer, M.D., Chief Executive Officer of Eyetech * Donald McDonald, M.D., Ph.D., Professor of Anatomy, University of California at San Francisco Comprehensive Cancer Center * David Shima, Ph.D., Senior Vice President of Research and Preclinical Development at Eyetech If you are unable to attend in person, you can access a live audio Web cast of the presentation by logging on to the Investor Relations section at http://www.eyetech.com/, or hear the audio portion of the Web cast by dialing 888-275-0218 (in the United States) or 706-679-7756 (internationally). (Logo: http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGO) http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGODATASOURCE: Eyetech Pharmaceuticals CONTACT: Susan Silao of Eyetech, +1-212-824-3175, ; or Shelly Nelson of Edelman for Eyetech Pharmaceuticals +1-212-819-4845, Web site: http://www.eyetech.com/

Copyright